False
May 12, 2026
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
6 min read
May 11, 2026
First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD
6 min read
May 5, 2026
Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody
4 min read
May 4, 2026
Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal
6 min read
April 28, 2026
FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars
4 min read
April 21, 2026
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
3 min read
April 20, 2026
Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T
4 min read
April 16, 2026
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently.
April 7, 2026
New Eveo system is designed to raise CAR-T output, cut manufacturing costs, and ease cleanroom bottlenecks
1 min read
April 3, 2026
New review maps how engineered regulatory T cells could calm brain inflammation in Alzheimer’s, Parkinson’s, ALS, and multiple sclerosis
1 min read
False